7,480 reports of this reaction
2.7% of all DENOSUMAB reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for DENOSUMAB, manufactured by Amgen, Inc. There are 7,480 FDA adverse event reports linking DENOSUMAB to FATIGUE. This represents approximately 2.7% of all 278,448 adverse event reports for this drug.
Patients taking DENOSUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for DENOSUMAB, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for DENOSUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 7,480 FDA reports for DENOSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.7% of all adverse event reports for DENOSUMAB, making it a notable side effect.
If you experience fatigue while taking DENOSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.